Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. See why RXRX stock is a Hold.

At least one of Recursion's partnerships has generated cash for the biotech so far in 2025, with the biotech reporting in May that Sanofi had paid a $7 million milestone after using Recursion's ...

Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...

Recursion states that REC-1245 is the first program using the company’s end-to-end AI platform, spanning discovery, biology, chemistry, and the clinic. According to Chris Gibson, CEO of ...

Spread the loveA factorial is a mathematical concept that is essential in many fields, including programming. In this article, we will delve into the world of factorials and how to calculate them ...

The cancer data that the startup generates and analyzes are different than what Recursion is working with. The tools are different too. Noetik was founded in mid-2022.

Recursion plans to use Nvidia's software to support its own pipeline, as well as its partners'. The Salt Lake City, Utah-based company's current partners include Bayer (BAYGn.DE) and Roche (ROG.S).

On May 8, Recursion Pharmaceuticals (RXRX 1.79%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock.

Since late 2017, Recursion has been able to get drug candidates ready to start human testing at just 20% of industry-average costs, while vetting molecules twice as fast, CEO Chris Gibson said.